US FDA extends review of Novo Nordisk's hemophilia drug over facility issues

The US FDA has extended its review of Novo Nordisk's experimental hemophilia A drug due ​to ongoing remediation work at a manufacturing facility, ‌the Danish drugmaker said on Friday.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。